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Contents l ists avai lable at ScienceDirectLetter and ReplyIs hypomagnesemia associated with using proton pump inhibitors?To the Editor:Proton pump inhibitors (PPIs) have been very useful in
various gastrointestinal diseases. However, hypomagnesemia
was reported in patients taking PPIs, and cross-sectional or
retrospective studies for a causal relationship between PPIs
and hypomagnesemia were carried out. Until now, this ques-
tion remains unresolved although a recent meta-analysis study
concluded that PPI use may increase the risk of hypomagnese-
mia [1].
In the past issue of this Journal, Park et al [2] added a con-
troversy to the association between hypomagnesemia and
the PPI use. This study was interesting because it was
performed on a relatively homogeneous population, who
was undergoing percutaneous coronary intervention and
whose basal serum magnesium level was normal. The
authors made an effort to demonstrate the relationship
through various subgroup analyses. However, in this study
protocol, the deﬁnition of PPI group is not sufﬁcient for
detailed history about taking PPIs, as it was uncertain when
PPI usage began.
The authors may need to show more data regarding
previous PPI usage, serum magnesium level before starting
PPIs, and the proportion of patients with previous
PPI usage before enrollment. Despite previous PPI usage,
some patients in the PPI group may consistently maintain
magnesium levels in normal range during the study period.
Furthermore, in the previous reports [3,4], the association
between PPI use and a low serum magnesium level was
observed among population with higher prevalence of hypo-
magnesemia, ranging from 6% to 24%. The authors already
pointed out a very low incidence of hypomagnesemia in the
study population. Unlike calcium balance, magnesium is not
readily mobilized from the bone stores. However, if negative
magnesium balance continues, the bone stores help tohttp://dx.doi.org/10.1016/j.krcp.2016.04.002
2211-9132/Copyright © 2016. The Korean Society of Nephrology. Published b
(http://creativecommons.org/licenses/by-nc-nd/4.0/).maintain serum magnesium concentration [5]. Therefore,
PPI exposure may induce only modest or no signiﬁcant
changes in serum magnesium concentration among patients
with normal range of serum magnesium.Conﬂicts of interest
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In reply:
We appreciate your interest in our recent article entitled
“Changes in serummagnesium concentration after use of a pro-
ton pump inhibitor in patients undergoing percutaneous coro-
nary intervention” [1]. Danziger et al [2] could demonstrate
that combined use of proton pump inhibitors (PPIs) and di-
uretics may increase the risk of hypomagnesemia, although
PPI use was not associated with serum magnesium levels
among those not using diuretics. A recently published meta-
analysis study suggested that the use of PPIs may be associated
with hypomagnesemia [3]. However, our study did not show a
relationship between PPI use and the occurrence of hypomag-
nesemia. In addition, a recent study showed that chronic PPI
use does not therefore appear to be associated with hypomag-
nesemia [4].
Inconsistent study results have prevented us from reaching
a solid conclusion. In a recent population-based cohort study,
PPI use was associated with hypomagnesemia; serum magne-
sium level was 0.022 mEq/L lower in PPI users compared
with nonusers [5]. In the clinical aspect, this lower level of
serum magnesium in PPI users may not be signiﬁcant. But
many case reports suggested that PPIs might be associated
with hypomagnesemia. Therefore, I think that further studies
should focus on the individual sensitivity of hypomagnesemia
after PPI use. Drug-induced hypomagnesemia is not unique to
PPIs. Other drugs such as gentamicin, calcineurin inhibitors,
platinum-based cytostatics, epidermal growth factor receptor
etargeting drugs, and diuretics have all been associated with
hypomagnesemia. These drugs affect magnesium active trans-
port channels, transient receptor potential melastatin subtype
6, which is responsible for the absorption of magnesium in
the kidney and intestine. Until now, it is not known whether
PPI therapy may disturb this transport system in the intestine.
Further study should reveal whether PPI affects this transport,
which can explain the mechanism of PPI-induced
hypomagnesemia.
We agree with your opinion that PPI exposure may induce
only modest or no signiﬁcant changes in serum magnesium
concentration among patients with normal range of serum
routinely measure magnesium levels after or before PPI use in
patients without risk factors, although the clinician should
know that PPI use could be associated with hypomagnesemia.
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